vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Global Business Travel Group, Inc. (GBTG). Click either name above to swap in a different company.
Global Business Travel Group, Inc. is the larger business by last-quarter revenue ($792.0M vs $598.7M, roughly 1.3× EXELIXIS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 10.5%, a 30.4% gap on every dollar of revenue. On growth, Global Business Travel Group, Inc. posted the faster year-over-year revenue change (34.0% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $13.0M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 13.9%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
A travel management company (TMC) is a travel agency which manages organizations' corporate or business travel programs. Such companies will often provide an end-user online booking tool, mobile application, program management, and consulting teams, executive travel services, meetings and events support, reporting functionality, duty of care, and more. Non-Profit travel management companies also provide services to manage complex visa requirements, pre-trip medical needs, remote area travel, ...
EXEL vs GBTG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $792.0M |
| Net Profit | $244.5M | $83.0M |
| Gross Margin | 95.6% | — |
| Operating Margin | 39.3% | 3.7% |
| Net Margin | 40.8% | 10.5% |
| Revenue YoY | 5.6% | 34.0% |
| Net Profit YoY | 74.8% | 692.9% |
| EPS (diluted) | $0.89 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $792.0M | ||
| Q3 25 | $568.3M | $674.0M | ||
| Q2 25 | $555.4M | $631.0M | ||
| Q1 25 | $566.8M | $621.0M | ||
| Q4 24 | — | $591.0M | ||
| Q3 24 | $539.5M | $597.0M | ||
| Q2 24 | $637.2M | $625.0M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $83.0M | ||
| Q3 25 | $184.8M | $-62.0M | ||
| Q2 25 | $159.6M | $15.0M | ||
| Q1 25 | $139.9M | $75.0M | ||
| Q4 24 | — | $-14.0M | ||
| Q3 24 | $118.0M | $-128.0M | ||
| Q2 24 | $226.1M | $27.0M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | — |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 3.7% | ||
| Q3 25 | 37.6% | 1.8% | ||
| Q2 25 | 33.6% | 5.4% | ||
| Q1 25 | 28.8% | 8.9% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | 25.2% | 4.5% | ||
| Q2 24 | 43.3% | 6.7% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 10.5% | ||
| Q3 25 | 32.5% | -9.2% | ||
| Q2 25 | 28.7% | 2.4% | ||
| Q1 25 | 24.7% | 12.1% | ||
| Q4 24 | — | -2.4% | ||
| Q3 24 | 21.9% | -21.4% | ||
| Q2 24 | 35.5% | 4.3% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $0.16 | ||
| Q3 25 | $0.65 | $-0.13 | ||
| Q2 25 | $0.55 | $0.03 | ||
| Q1 25 | $0.47 | $0.16 | ||
| Q4 24 | — | $-0.04 | ||
| Q3 24 | $0.40 | $-0.28 | ||
| Q2 24 | $0.77 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $434.0M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $2.2B | $1.6B |
| Total Assets | $2.8B | $4.9B |
| Debt / EquityLower = less leverage | — | 0.88× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $434.0M | ||
| Q3 25 | $791.1M | $427.0M | ||
| Q2 25 | $1.0B | $601.0M | ||
| Q1 25 | $1.1B | $552.0M | ||
| Q4 24 | — | $536.0M | ||
| Q3 24 | $1.2B | $524.0M | ||
| Q2 24 | $1.0B | $515.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | — |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $1.6B | ||
| Q3 25 | $2.0B | $1.5B | ||
| Q2 25 | $2.1B | $1.2B | ||
| Q1 25 | $2.2B | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $2.3B | $1.1B | ||
| Q2 24 | $2.1B | $1.2B |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $4.9B | ||
| Q3 25 | $2.7B | $4.8B | ||
| Q2 25 | $2.8B | $3.9B | ||
| Q1 25 | $2.9B | $3.8B | ||
| Q4 24 | — | $3.6B | ||
| Q3 24 | $3.0B | $3.8B | ||
| Q2 24 | $2.8B | $3.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.88× | ||
| Q3 25 | — | 0.91× | ||
| Q2 25 | — | 1.15× | ||
| Q1 25 | — | 1.23× | ||
| Q4 24 | — | 1.32× | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $52.0M |
| Free Cash FlowOCF − Capex | $332.4M | $13.0M |
| FCF MarginFCF / Revenue | 55.5% | 1.6% |
| Capex IntensityCapex / Revenue | 0.2% | 4.9% |
| Cash ConversionOCF / Net Profit | 1.36× | 0.63× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $104.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $52.0M | ||
| Q3 25 | $49.0M | $71.0M | ||
| Q2 25 | $211.4M | $57.0M | ||
| Q1 25 | $240.3M | $53.0M | ||
| Q4 24 | — | $65.0M | ||
| Q3 24 | $271.3M | $85.0M | ||
| Q2 24 | $119.5M | $73.0M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $13.0M | ||
| Q3 25 | $46.2M | $38.0M | ||
| Q2 25 | $208.5M | $27.0M | ||
| Q1 25 | $236.3M | $26.0M | ||
| Q4 24 | — | $33.0M | ||
| Q3 24 | $263.1M | $59.0M | ||
| Q2 24 | $113.0M | $49.0M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 1.6% | ||
| Q3 25 | 8.1% | 5.6% | ||
| Q2 25 | 37.5% | 4.3% | ||
| Q1 25 | 41.7% | 4.2% | ||
| Q4 24 | — | 5.6% | ||
| Q3 24 | 48.8% | 9.9% | ||
| Q2 24 | 17.7% | 7.8% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 4.9% | ||
| Q3 25 | 0.5% | 4.9% | ||
| Q2 25 | 0.5% | 4.8% | ||
| Q1 25 | 0.7% | 4.3% | ||
| Q4 24 | — | 5.4% | ||
| Q3 24 | 1.5% | 4.4% | ||
| Q2 24 | 1.0% | 3.8% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 0.63× | ||
| Q3 25 | 0.27× | — | ||
| Q2 25 | 1.32× | 3.80× | ||
| Q1 25 | 1.72× | 0.71× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.30× | — | ||
| Q2 24 | 0.53× | 2.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
GBTG
| Travel | $620.0M | 78% |
| Other | $172.0M | 22% |
